InspireMD to Host Key Opinion Leader Event on Carotid Artery Disease Management and Stroke Prevention in combination with the CGuard™ Stent Platform & MicroNet™ Portfolio
16 mars 2022 16h05 HE
|
InspireMD Inc.
TEL AVIV, Israel, March 16, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid...
InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results
08 mars 2022 07h30 HE
|
InspireMD Inc.
- CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year –- - Published CGuard Clinical trial results in Journals of the American College of Cardiology - -...
InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application
28 févr. 2022 07h00 HE
|
InspireMD Inc.
- CGuard™ Carotid Stent will now be a treatment option in the stenting plus medical therapy arm of the trial for patients - - CREST-2 Trial is sponsored by the National Institute of Neurological...
InspireMD to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 and Provide Corporate Business Update
22 févr. 2022 16h30 HE
|
InspireMD Inc.
-Earnings Conference Call to be held Tuesday, March 8, 2022, at 8:30 a.m. ET- TEL AVIV, Israel, Feb. 22, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™...
InspireMD Announces Adnan Siddiqui, MD, PhD as a Member of its Scientific Advisory Board and Strategic Advisor
15 févr. 2022 08h00 HE
|
InspireMD Inc.
TEL AVIV, Israel, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery...
InspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS)
27 janv. 2022 08h00 HE
|
InspireMD Inc.
TEL AVIV, Israel, Jan. 27, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery...
InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial
18 janv. 2022 08h11 HE
|
InspireMD Inc.
TEL AVIV, Israel, Jan. 18, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery...
InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update
09 nov. 2021 07h30 HE
|
InspireMD Inc.
-CGuard™ sales generated 24% YoY revenue growth- -CGuard™ EPS received a positive opinion from the French National Authority for Health (HAS) regarding reimbursement in France- - $37.1 million in...
InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions
03 nov. 2021 16h05 HE
|
InspireMD Inc.
TEL AVIV, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of...
InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update
26 oct. 2021 08h30 HE
|
InspireMD Inc.
TEL AVIV, Israel, Oct. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...